142 related articles for article (PubMed ID: 24375481)
1. Chromogranin A staining as a prognostic variable in newly diagnosed Gleason score 7-10 prostate cancer treated with definitive radiotherapy.
Krauss DJ; Amin M; Stone B; Ye H; Hayek S; Cotant M; Hafron J; Brabbins DS
Prostate; 2014 May; 74(5):520-7. PubMed ID: 24375481
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of neuroendocrine differentiation in patients with Gleason score 8-10 prostate cancer treated with primary radiotherapy.
Krauss DJ; Hayek S; Amin M; Ye H; Kestin LL; Zadora S; Vicini FA; Cotant M; Brabbins DS; Ghilezan MI; Gustafson GS; Martinez AA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e119-25. PubMed ID: 21596486
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the Prognostic Significance of Neuroendocrine Differentiation in Gleason Score 7 to 10 Prostate Adenocarcinoma in Patients With Distant Metastasis After Definitive Radiotherapy.
Mankuzhy NP; Almahariq MF; Ye H; Amin M; Stone B; Krauss DJ
Am J Clin Pathol; 2021 May; 155(6):879-886. PubMed ID: 33283224
[TBL] [Abstract][Full Text] [Related]
4. Prognostic importance of Gleason 7 disease among patients treated with external beam radiation therapy for prostate cancer: results of a detailed biopsy core analysis.
Spratt DE; Zumsteg Z; Ghadjar P; Pangasa M; Pei X; Fine SW; Yamada Y; Kollmeier M; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1254-61. PubMed ID: 23182392
[TBL] [Abstract][Full Text] [Related]
5. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
6. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy.
Berruti A; Bollito E; Cracco CM; Volante M; Ciccone G; Porpiglia F; Papotti M; Scarpa RM; Dogliotti L
Prostate; 2010 May; 70(7):718-26. PubMed ID: 20087896
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.
Quek ML; Daneshmand S; Rodrigo S; Cai J; Dorff TB; Groshen S; Skinner DG; Lieskovsky G; Pinski J
Urology; 2006 Jun; 67(6):1247-52. PubMed ID: 16697447
[TBL] [Abstract][Full Text] [Related]
8. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
9. Distant metastases following permanent interstitial brachytherapy for patients with clinically localized prostate cancer.
Taira AV; Merrick GS; Galbreath RW; Butler WM; Lief J; Adamovich E; Wallner KE
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e225-32. PubMed ID: 21664066
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
[TBL] [Abstract][Full Text] [Related]
11. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
12. Gleason score 7 prostate cancer treated with interstitial brachytherapy with or without supplemental external beam radiation and androgen deprivation therapy: is the primary pattern on needle biopsy prognostic?
Bittner N; Merrick GS; Butler WM; Galbreath RW; Adamovich E; Wallner KE
Brachytherapy; 2013; 12(1):14-8. PubMed ID: 22884256
[TBL] [Abstract][Full Text] [Related]
13. Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma.
Sciarra A; Di Silverio F; Autran AM; Salciccia S; Gentilucci A; Alfarone A; Gentile V
Urol Int; 2009; 82(2):147-51. PubMed ID: 19321999
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical study of chromogranin A in Stage D2 prostate cancer.
Kokubo H; Yamada Y; Nishio Y; Fukatsu H; Honda N; Nakagawa A; Saga S; Tsuzuki T; Hara K
Urology; 2005 Jul; 66(1):135-40. PubMed ID: 15992907
[TBL] [Abstract][Full Text] [Related]
15. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102
[TBL] [Abstract][Full Text] [Related]
16. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
[TBL] [Abstract][Full Text] [Related]
17. Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies.
Casella R; Bubendorf L; Sauter G; Moch H; Mihatsch MJ; Gasser TC
J Urol; 1998 Aug; 160(2):406-10. PubMed ID: 9679888
[TBL] [Abstract][Full Text] [Related]
18. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
Vargas C; MartÃnez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
[TBL] [Abstract][Full Text] [Related]
19. Percentage of positive biopsy cores: a better risk stratification model for prostate cancer?
Huang J; Vicini FA; Williams SG; Ye H; McGrath S; Ghilezan M; Krauss D; Martinez AA; Kestin LL
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1141-8. PubMed ID: 22099043
[TBL] [Abstract][Full Text] [Related]
20. Percentage of cancer volume in biopsy cores is prognostic for prostate cancer death and overall survival in patients treated with dose-escalated external beam radiotherapy.
Vance SM; Stenmark MH; Blas K; Halverson S; Hamstra DA; Feng FY
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):940-6. PubMed ID: 22056069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
